|
News for Santarus Inc.
(SNTS)
|
|
|
|
After Hours:
$ 22.56
|
0.00 (0.00%)
|
Volume: 50.18 k
|
4:11 PM EDT May 24, 2013
|
|
|
|
|
|
|
|
|
| 9:30 AM
|
The Zacks Analyst Blog Highlights: Zumiez, Mylan, AbbVie, Santarus and Jazz Pharmaceuticals
- PR Newswire
|
|
|
|
| 9:30 AM
|
Zacks Bull and Bear of the Day Highlights: Santarus, Nuance Communications, Sprint Nextel, DISH Network and Verizon Communications
- PR Newswire
|
|
|
|
| 7:00 AM
|
Santarus Announces UCERIS (budesonide) Poster Presentations at Digestive Disease Week Meeting
- Business Wire
|
|
|
|
| 4:05 PM
|
Santarus Announces Exercise in Full of Option to Purchase Additional Shares and Completion of Secondary Common Stock Offering
- Business Wire
|
|
|
|
| 9:04 AM
|
Santarus Announces Pricing of Secondary Common Stock Offering by a Selling Stockholder
- Business Wire
|
|
|
|
| 4:01 PM
|
Santarus Announces Launch of a Proposed Secondary Common Stock Offering by a Selling Stockholder
- Business Wire
|
|
|
|
| 8:20 AM
|
Free Research Reports on ARRY, DTV, NLS and SNTS Issued by the Paragon Report
- Marketwired
|
|
|
|
| 4:05 PM
|
Santarus Reports First Quarter 2013 Financial Results
- Business Wire
|
|
|
|
| 7:00 AM
|
Santarus to Present at May and June Investment Conferences
- Business Wire
|
|
|
|
| 7:00 AM
|
CYCLOSET (bromocriptine mesylate) Included in American Association of Clinical Endocrinologists Comprehensive Diabetes Management Algorithm
- Business Wire
|
|
|
|
| 7:00 AM
|
Santarus to Hold First Quarter 2013 Financial Results Conference Call on May 6
- Business Wire
|
|
|
|
| 1:00 AM
|
Santarus and Pharming Announce Submission of RUCONEST Biologics License Application to FDA
- Business Wire
|
|
|
|
| 10:00 AM
|
Santarus, Inc. [SNTS] to Ring The NASDAQ Stock Market Closing Bell
- Globe Newswire
|
|
|
|
| 8:20 AM
|
Free Research Reports on ARNA, MT, NVAX and SNTS Issued by the Paragon Report
- Marketwired
|
|
|
|
| 7:00 AM
|
Santarus to Host Investor and Analyst Day on April 11, 2013
- Marketwired
|
|
|
|
| 8:00 AM
|
Before the Bell Scans of MannKind, Ariad Pharma, ZIOPHARM Oncology, NPS Pharma, and Santarus
- PR Newswire
|
|
|
|
| 7:00 AM
|
Santarus Announces Publication in Gut of Results from UCERIS (budesonide) European Pivotal Clinical Study
- Business Wire
|
|
|
|
| 8:20 AM
|
Biotech Industry Looks to Benefit From FDA's New "Breakthrough" Designation
- Marketwired
|
|
|
|
| 8:00 AM
|
Pushing Pipelines Forward for Long-Term Success - Research Report on Vertex, Santarus, Arena Pharmaceuticals, Seattle Genetics and Nektar Therapeutics
- PR Newswire
|
|
|
|
| 8:15 AM
|
Free Research Reports on ACUR, IPXL, SNTS and ASNA Issued by the Bedford Report
- Marketwired
|
| 7:00 AM
|
Santarus and VeroScience Announce Publication of AACE Expert Panel Recommendations for CYCLOSETu00AE (bromocriptine mesylate) for the Management of Type 2 Diabetes
- Business Wire
|
|
|
|
| 4:05 PM
|
Santarus Reports Fourth Quarter and Full Year 2012 Financial Results
- Business Wire
|
|
|
|
| 7:00 AM
|
Santarus to Present at March Investment Conferences
- Business Wire
|
|
|
|
| 8:20 AM
|
U.S. Food and Drug Administration Approved 30% More Drugs in 2012
- Marketwired
|
|
|
|
| 8:45 AM
|
Free Research Reports on RSYS, SNTS, VPHM and VRTX Issued by the Bedford Report
- Marketwired
|
|
|
|
|
